40 results about "Ocular irritation" patented technology

A method for treating a patient having meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion, is disclosed. Preferably, the method concerns treatment of a patient with topical tetracycline, a derivative or analogue of tetracycline, or a chemically modified tetracycline (CMT). Oral administration of a CMT is also disclosed as part of the method for treating meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion.

Mild shampoo compositions are described that are economical, have excellent in-use properties, and provide enhanced conditioning benefits. The compositions have low ocular irritation potential and are particularly suitable for use by children. The compositions include a surfactant system composed on an alkyl ethoxy sulfate having at least 3 ethylene oxide groups, a betaine surfactant, and an hydroxysultaine surfactant in specific ratios; and a non-volatile water-insoluble silicone. In-vitro tests are described that allows selection of optional ingredients that do not compromise the mildness or hair conditioning performance of the composition.

The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye. Methods of manufacture are also provided.

The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye.

The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye.

The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye.

The invention discloses a method for the multi-parameter detection of ocular irritation by using an in-vitro animal cornea model. The method comprises the following steps: 1) preparing and keeping an in-vitro animal cornea; 2) exposing a test substance; concentration of a test substance, and determining the concentration of the test substance, the exposure time, and the post-incubation time; 3) selecting the evaluation parameters of the test substance; 4) measuring the evaluation parameters; 5) evaluating and predicting the ocular irritation of the test substance. The in-vitro animal cornea is similar to a human cornea and has normal physiological activity after undergoing short-time in vitro keeping maintenance, and the multiple evaluation parameters are measured and analyzed after the test substance is in contact with the cornea in order to evaluate the influences of the test substance on the cornea after repeated/multiple exposure, and the potential ocular irritation is predicted. The method disclosed in the invention can replace traditional Draize rabbit eye test, can be directly used to compare, evaluate and predict the potential ocular irritation of daily chemical products, chemicals, medicines and other products/raw materials/formulas, and has the advantages of high flux, low cost and short time.

Disclosed are compositions and methods comprising povidone-iodine and a cooling-effective amount of a chemical agent. The compositions are useful to relieve mild ocular irritation, enhance ocular comfort, and to provide a refreshing effect and improved sensation, when the povidone-iodine solution is applied to the eye.

The present invention discloses an experimental method for evaluating eye irritation by using miniature pig erythrocytes. The method mainly comprises: (1) preparing a suspension of miniature pig erythrocytes; (2) carrying out a miniature pig erythrocyte hemolysis test; (3) carrying out a protein denaturation experiment; (4) predicting a model; (5) carrying out classification and judgment. According to the present invention, the source of the erythrocytes is reliable and safe; the tested material is easy to obtain, and has good uniformity; the test system is simple and cheap, and no special equipment is required; the detection method is rapid, sensitive and universal; the method of the present invention can be directly applicable for safety evaluations of chemicals, cosmetics, pesticides, eye medicines and other substances possibly contacting the eyes, wherein the chemicals comprise surfactants, disinfection products, detergent and the like, the cosmetics comprise shampoo, bath foam, eye cream and the like; the method further can be applicable for rapidly screening, classifying and identifying the eye irritations of the raw materials, the formulas or the products.

The present invention provides compositions comprising a low dose amount of an ophthalmic NSAID for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye and safe for chronic use.

The invention discloses an antipruritic and anti-allergic baby washing and protecting preparation and an application thereof. The antipruritic and anti-allergic baby washing and protecting preparations comprises a wild chrysanthemum flower extract, a dandelion extract, a milkvetch root extract, and a bitter apricot seed extract. The antipruritic and anti-allergic baby washing and protecting preparation contains mild and natural plant extracts, the addition of irritant substances is avoided from the raw materials, the irritation of the product is reduced, and the relatively good experience sense, and relatively strong anti-allergenicity and antipruritic performance are realized through the synergistic compatibility effects of the specific components. The patch test results show that the washing and protecting preparation is a negative result, and does not have irritation to the skin, the eye irritation test results show a NC value of less than or equal to 2, the washing and protecting preparation is the stress irritation, namely, is damage-free irritation, has no eye irritation, and is safe and mild. In addition, a foam volume of the product can reach 770 mL, the time of discharging50 mL of a liquid by foam can reach 11.8 s, the foaming ability is strong, the foam stability is good, and thereby the washing and protecting preparation can be widely used in the preparation of infants and young children products.

The present invention relates to a delivery system for ophthalmic drugs, and more particularly, to a non aqueous oil delivery system. Low concentrations of ophthalmic drugs suspended in an oil vehicle delivery system are as therapeutically effective in man and animals as the corresponding higher concentrations of ophthalmic drugs that are commercially used in aqueous solutions. Eye drops that utilize this nonaqueous oil delivery system, when used in man, are comfortable to use and produce little ocular irritation, have a longer shelf-life, low systemic toxic potential, and only short term blurring of vision. Using this nonaqueous oil delivery system, a single drop of ophthalmic drug with a concentration that is 10 times less than the same drug used in commercially available aqueous eye drops is as effective as the commercially available aqueous ophthalmic eye drops that require many applications to be effective. In addition, utilizing the nonaqueous oil delivery system as eye drops produces no ocular sensation of burning, stinging or excessive tearing that is commonly associated with the commercially available aqueous eye drops. This very dilute ophthalmic drug preparation has a greatly reduced systemic toxicity potential as compared to the commercially used aqueous ophthalmic drops. The vehicle includes castor oil, corn oil, glycerol, mineral oil USP, vegetable oil, white petrolatum USP, and mixtures, there of. The ophthalmic class of drugs includes antimicrobials, miotics, mydriatics, mydriatic-cycloplegics, mydriatic-cycloplegic reversal agents and topical anesthetics.

The invention relates to the technical field of cosmetics with the IPC classification number of A61K8/92, in particular to soothing and anti-inflammatory cleansing oil and a preparation method thereof. The cleansing oil is prepared from the following raw materials: 2wt%-10wt% of effective components and 90wt%-98wt% of main components, wherein the effective components comprise a water-containing emulsifier and a water-soluble active matter; the weight ratio of the water-containing emulsifier to the water-soluble active matter is 1: (0.5-5). According to the cleansing oil disclosed by the invention, water-soluble active substances can be added, and the addition amount of the water-soluble active substances is higher than that of the active substances in the prior art, so that the cleansing effect of the cleansing oil cannot be influenced when the higher active substances are added, the cleansing oil can be normally used, and after water is added for cleansing, the eye irritation is obviously improved.

Methods of determining a level of ocular irritation and/or toxicity for a chemical compound are described. Kits for use in methods of determining a level of ocular irritation and/or toxicity for a chemical compound are also described.

The invention provides cleansing paste. The cleansing paste comprises the following components in percentage by mass: 8-35% of a nonionic surfactant, 20-75% of grease, 5-25% of a humectant and the balance of water, the overall HLB (Hydrophile Lipophile Balance) value of the nonionic surfactant is 8 to 13. The cleansing paste disclosed by the invention has an excellent cleansing effect like cleansing oil and also has easy washing performance and soft texture like cleansing gel, gel formed after shaking up is easy to push away when being smeared, is not easy to drop from the face and not easy to enter eyes to cause eye irritation, does not generate gelation when being washed, can generate color change in a layering process, and has superiority in aesthetics. After washing, the fabric is not tight and has a certain moist feeling.

The invention discloses a method for predicting eye irritation by using various corneal structure cell combinations. The method comprises the following steps of (1) predicting the irritation of corneal epithelial cells; (2) predicting the irritation of corneal stromal fibroblasts, wherein (2.1) neutral red release (NRR) testing is carried out and (2.2) inflammatory factor testing is carried out; (3) predicting the irritation of corneal endothelial cells; and (4) predicting the establishment of an eye irritation model based on various corneal structure cell combinations. The method can comprehensively reflect the toxic effect of a tested substance (such as a stimulant or a corrosive substance) on corneal structure cells; non-animal testing is realized; the irritation degree of eye irritation substances can be predicted; data information is rich; and the method can be widely applied.

The present invention relates to an ophthalmic composition comprising pranoprofen and olopatadine and/or naphazoline. The invention also relates to a preparation method of the ophthalmic composition, which comprises the following steps: mixing the pranoprofen, the olopatadine and/or the naphazoline, the osmotic pressure regulator, the pH regulator, the metal ion chelating agent, the thickening agent, the preservative and the water for injection to obtain the ophthalmic composition. The invention also relates to an application of the ophthalmic composition in preparation of a medicine for treating ocular inflammation, and the ocular inflammation comprises external eye and/or anterior segment inflammation caused by gram-positive bacterium and/or gram-negative bacterium infection. When the ophthalmic composition provided by the invention is used as eye drops, the treatment effect on eye inflammation of a patient can be improved, and adverse effects of eye stimulation, conjunctival congestion, edema and the like after medication can be avoided, so that the medication compliance of the patient is improved, and the recovery time of the patient is shortened.

The invention relates to a cold spraying modified layer and application thereof. In the process of preparing hydroxyapatite nano-powder, a surfactant is added to be beneficial to reducing the particle size of the nano-powder, and the change can optimize the biocompatibility, corrosion resistance and eye irritation of the cold spraying modified layer in later. However, after four different kinds of surfactants (sodium dodecyl benzene sulfonate, mannosylerythritol lipid, rhamnolipid and sophorolipid) are compared, it is found that the sodium dodecyl benzene sulfonate is not beneficial to the cytotoxicity and eye irritation of the modified layer of an artificial cornea titanium bracket, the reason possibly lies in that the whole preparation technology can hardly realize 100% removal of the surfactant, and compared with sodium dodecyl benzene sulfonate, mannosylerythritol lipid, rhamnolipid, sophorolipid and other glycolipid biosurfactants, proliferation and growth of cells are more facilitated.